tiprankstipranks
Trending News
More News >
Blue Jet Healthcare Limited (IN:BLUEJET)
:BLUEJET
India Market
Advertisement

Blue Jet Healthcare Limited (BLUEJET) AI Stock Analysis

Compare
4 Followers

Top Page

IN:BLUEJET

Blue Jet Healthcare Limited

(BLUEJET)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - 4o)
Rating:61Neutral
Price Target:
₹592.00
▼(-9.40% Downside)
Blue Jet Healthcare's overall stock score is driven by its strong financial performance, particularly in revenue growth and profitability. However, technical analysis indicates bearish momentum, and valuation metrics suggest moderate valuation with limited dividend yield. The absence of earnings call data and corporate events did not impact the score.
Positive Factors
Revenue Growth
The robust revenue growth of 45.01% indicates strong market demand and effective sales strategies, supporting long-term business expansion.
Profitability
Improved net profit margin reflects efficient cost management and pricing power, enhancing the company's ability to generate sustainable profits.
Balance Sheet Health
Minimal leverage and high equity ratio indicate financial stability, reducing risk and enhancing the company's ability to invest in growth opportunities.
Negative Factors
Cash Flow Challenges
Negative free cash flow suggests difficulties in cash generation, potentially limiting the company's ability to fund operations and growth initiatives.
Cash Conversion Efficiency
Low cash conversion efficiency indicates challenges in converting profits into cash, which may affect liquidity and operational flexibility.
Lack of Earnings Call Data
The absence of earnings call insights limits transparency and investor understanding of management's strategic direction and future outlook.

Blue Jet Healthcare Limited (BLUEJET) vs. iShares MSCI India ETF (INDA)

Blue Jet Healthcare Limited Business Overview & Revenue Model

Company DescriptionBlue Jet Healthcare Limited (BLUEJET) is a dynamic player in the healthcare sector, focusing on the development and distribution of innovative medical products and services. The company operates primarily in the pharmaceuticals and medical devices sectors, offering a wide range of healthcare solutions designed to enhance patient care and operational efficiency in healthcare facilities. Core products include advanced medical devices, diagnostic tools, and a portfolio of pharmaceutical products aimed at addressing various health conditions.
How the Company Makes MoneyBLUEJET generates revenue through multiple streams, including the sale of pharmaceutical products and medical devices to hospitals, clinics, and healthcare providers. The company also engages in long-term contracts with healthcare institutions for the supply of essential medical supplies, which provides a stable revenue base. Additionally, BLUEJET may collaborate with research organizations and healthcare providers to develop new products, often securing funding or revenue-sharing agreements as part of these partnerships. The company's focus on innovation allows it to stay competitive in the market, driving sales through both direct product offerings and strategic partnerships.

Blue Jet Healthcare Limited Financial Statement Overview

Summary
Blue Jet Healthcare exhibits strong financial performance with significant revenue growth and profitability, as evidenced by robust margins and a stable balance sheet with minimal leverage. However, challenges in free cash flow generation present a potential area of concern.
Income Statement
85
Very Positive
Blue Jet Healthcare has demonstrated strong financial performance with significant growth in total revenue from ₹7,103 million in 2024 to ₹10,299 million in 2025, reflecting a robust revenue growth rate of 45.01%. The gross profit margin improved to 55.24% in 2025, indicating efficient cost management. The net profit margin also increased to 29.65%, reflecting higher profitability. EBIT and EBITDA margins are solid at 49.30% and 41.18%, respectively. Overall, the income statement shows excellent growth and profitability.
Balance Sheet
82
Very Positive
The balance sheet of Blue Jet Healthcare reveals strong financial health with a low debt-to-equity ratio of 0.02, indicating minimal leverage. The equity ratio stands at 79.94%, showcasing a high level of financial stability. Return on equity (ROE) is impressive at 26.93%, reflecting effective use of equity to generate profits. The company's significant equity base and low debt level highlight its stability and low risk.
Cash Flow
72
Positive
Blue Jet Healthcare's cash flow performance is mixed. The operating cash flow to net income ratio is 0.15, suggesting lower cash conversion efficiency. However, the free cash flow to net income ratio is negative due to the decrease in free cash flow from ₹669 million in 2024 to -₹341 million in 2025, indicating challenges in generating free cash flow. While the company maintains positive operating cash flow, the pressure on free cash flow presents a potential area of concern.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue12.22B10.30B7.10B7.18B6.77B4.94B
Gross Profit6.32B5.69B3.89B2.70B2.97B2.47B
EBITDA4.88B4.24B2.48B2.43B2.69B2.15B
Net Income3.59B3.05B1.64B1.60B1.82B1.38B
Balance Sheet
Total Assets0.0014.18B10.59B8.62B7.13B5.36B
Cash, Cash Equivalents and Short-Term Investments3.06B3.06B3.09B2.55B1.81B979.70M
Total Debt0.00199.86M16.13M68.31M228.39M516.15M
Total Liabilities-11.33B2.84B2.14B1.81B1.92B1.96B
Stockholders Equity11.33B11.33B8.45B6.81B5.22B3.40B
Cash Flow
Free Cash Flow0.00-341.15M669.59M822.79M1.21B807.67M
Operating Cash Flow0.00457.65M2.41B1.42B1.46B1.30B
Investing Cash Flow0.00-351.83M-2.64B-1.47B-760.26M-566.48M
Financing Cash Flow0.00-185.57M-19.86M-42.33M-561.45M-221.90M

Blue Jet Healthcare Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price653.45
Price Trends
50DMA
638.88
Negative
100DMA
722.69
Negative
200DMA
767.51
Negative
Market Momentum
MACD
-25.72
Positive
RSI
39.36
Neutral
STOCH
21.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Negative. The current price of 653.45 is above the 20-day moving average (MA) of 595.37, above the 50-day MA of 638.88, and below the 200-day MA of 767.51, indicating a bearish trend. The MACD of -25.72 indicates Positive momentum. The RSI at 39.36 is Neutral, neither overbought nor oversold. The STOCH value of 21.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BLUEJET.

Blue Jet Healthcare Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
₹61.76B33.860.13%14.35%15.79%
71
Outperform
₹260.38B51.130.19%8.57%-2.93%
63
Neutral
₹531.84B100.380.13%10.62%-66.88%
63
Neutral
₹115.63B39.760.70%3.80%64.94%
61
Neutral
₹98.96B28.080.21%63.34%109.89%
61
Neutral
₹152.42B42.800.76%3.63%-1.21%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:BLUEJET
Blue Jet Healthcare Limited
575.45
52.57
10.05%
IN:BIOCON
Biocon Limited
399.55
36.24
9.97%
IN:CONCORDBIO
Concord Biotech Ltd.
1,441.45
-582.17
-28.77%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
711.50
-25.08
-3.40%
IN:SUPRIYA
Supriya Lifescience Limited
767.40
10.70
1.41%
IN:SYNGENE
Syngene International Ltd.
640.50
-273.43
-29.92%

Blue Jet Healthcare Limited Corporate Events

Blue Jet Healthcare Confirms Compliance with SEBI Regulations
Oct 7, 2025

Blue Jet Healthcare Limited has announced that it has complied with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as confirmed by its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The company stated that all its shares are held in dematerialized form, and no requests for rematerialization were received during the quarter ended September 30, 2025, indicating streamlined operations and compliance with regulatory requirements.

Blue Jet Healthcare’s 57th AGM Highlights Strategy and Performance
Sep 26, 2025

Blue Jet Healthcare Limited held its 57th Annual General Meeting on September 26, 2025, through video conferencing, in compliance with regulatory guidelines. The meeting was chaired by Mr. Akshay Bansarial Arora and attended by all directors and committee chairpersons. Key topics included the company’s strategies and performance for FY 2024-25, with all necessary documents made available for electronic inspection. The Auditor’s Report was accepted without any qualifications or adverse remarks.

Blue Jet Healthcare to Participate in Kotak Healthcare Forum
Sep 18, 2025

Blue Jet Healthcare Limited has announced its participation in the Kotak Healthcare Forum, scheduled for September 19, 2025, where it will engage in a one-to-one investor meeting. This engagement is part of the company’s efforts to maintain transparency with its stakeholders, ensuring that no unpublished price-sensitive information is disclosed during the meeting.

Blue Jet Healthcare Announces Key Appointments and Dividend Details
Aug 22, 2025

Blue Jet Healthcare Limited announced several key decisions following its board meeting on August 22, 2025. The company has appointed M/s. Mehta & Mehta as its secretarial auditors for five years and re-appointed Mr. Naresh Suryakant Shah as a Whole-Time Director for another five-year term. Additionally, Mr. Popat Bhagwan Kedar has been re-designated as a Whole-Time Director for a similar period. The company has set a record date of September 19, 2025, for dividend entitlement and scheduled its 57th Annual General Meeting for September 26, 2025. These decisions are expected to strengthen the company’s governance and operational continuity, potentially enhancing shareholder value.

Blue Jet Healthcare Announces Board Changes and Dividend Declaration
Aug 22, 2025

Blue Jet Healthcare Limited announced significant changes in its board of directors, including the appointment of Mehta & Mehta as Secretarial Auditors for five years and the re-appointment of Mr. Naresh Suryakant Shah and re-designation of Mr. Popat Bhagwan Kedar as Whole-Time Directors. Additionally, the company declared a final dividend of Rs. 1.2 per equity share and scheduled its 57th Annual General Meeting for September 26, 2025, indicating a strategic focus on governance and shareholder value.

Blue Jet Healthcare Announces Key Appointments and Dividend Declaration
Aug 22, 2025

Blue Jet Healthcare Limited announced significant changes in its corporate governance and financial operations following a board meeting. The company appointed M/s. Mehta & Mehta as Secretarial Auditors for a five-year term, re-appointed Mr. Naresh Suryakant Shah as Whole-Time Director, and re-designated Mr. Popat Bhagwan Kedar as Whole-Time Director, all subject to shareholder approval. Additionally, the company declared a dividend of Rs. 1.2 per share and scheduled its 57th Annual General Meeting for September 26, 2025.

Blue Jet Healthcare Announces Key Appointments and Dividend Details
Aug 22, 2025

Blue Jet Healthcare Limited, a company listed on the BSE and NSE, announced several key decisions following its board meeting on August 22, 2025. The board approved the appointment of M/s. Mehta & Mehta as Secretarial Auditors for a five-year term and re-appointed Mr. Naresh Suryakant Shah and re-designated Mr. Popat Bhagwan Kedar as Whole-Time Directors for five years, subject to shareholder approval. Additionally, the company set September 19, 2025, as the record date for a dividend of Rs. 1.2 per share, with payment due by October 25, 2025. The 57th Annual General Meeting is scheduled for September 26, 2025.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 07, 2025